Curio Digital Therapeutics, a New Jersey-based company pioneering digital health solutions for women, has recently secured a significant ‘double-digit million’ investment during its latest funding round. This financial success was achieved with contributions from RYSE Asset Management, ONCE—the nutraceuticals venture capital branch of Otsuka—Bridge Point Capital, and Avestria. Curio’s primary focus is on addressing mental health conditions such as postpartum depression (PPD) through innovative digital interventions. This emphasis on mental health comes at a time when traditional therapeutic avenues are being complemented by digital health technologies, aiming to provide more accessible, effective, and scalable solutions.
MamaLift Plus: A Breakthrough in Postpartum Depression Treatment
Curio’s flagship product, MamaLift Plus, has reached several significant milestones, notably receiving FDA approval as a Software as a Medical Device (SaMD) Class 2. This regulatory green light marks MamaLift Plus as the first prescription digital therapeutic specifically engineered for the treatment of postpartum depression in women aged 22 years and older. Administered over an eight-week period concurrently with clinician-managed outpatient care, MamaLift Plus offers a structured approach to combating this prevalent mental health condition, affecting roughly one in seven women after childbirth. The therapeutic framework integrates seamlessly with standard medical practices, aiming to fill gaps left by conventional treatments.
A standout feature of MamaLift Plus is its Connected Care platform, which meticulously evaluates a woman’s risk of depression and facilitates coordinated treatment through her healthcare providers. This capability enhances the monitoring and treatment efforts of clinicians, enabling a comprehensive approach to patient care. The platform allows healthcare providers to report on the depression levels of their patients, ensuring a continuous and informed treatment process. This level of integration signifies a substantial advancement in how postpartum depression is addressed, potentially setting a benchmark for future digital health interventions targeting women-specific conditions.
Expanding Horizons and Strategic Partnerships
Curio Digital Therapeutics, a company based in New Jersey, is at the forefront of pioneering digital health solutions for women. Recently, Curio secured a large investment, described as being in the ‘double-digit million’ range, in its most recent funding round. This financial achievement was made possible thanks to contributions from RYSE Asset Management, ONCE—the nutraceuticals venture capital arm of Otsuka—Bridge Point Capital, and Avestria. The company’s primary mission is to tackle mental health issues, particularly postpartum depression (PPD), through innovative digital interventions. This focus on mental health comes at a significant time when traditional therapeutic approaches are being supplemented by digital health technologies. These new methods aim to provide more accessible, effective, and scalable solutions. With this investment, Curio is poised to further advance its cutting-edge work in the digital mental health space, offering innovative solutions that are timely and much needed in today’s healthcare landscape.
